[ CAS No. 848438-50-6 ] {[proInfo.proName]}

Name: 848438-50-6|4-Chloroquinazolin-6-ol|95%
Brand: Ambeed
SKU: A250694
Rating: 90 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 848438-50-6

Structure of 848438-50-6 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 848438-50-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 848438-50-6 ]

SDS Specification

Alternatived Products of [ 848438-50-6 ]

Product Details of [ 848438-50-6 ]

CAS No. :	848438-50-6	MDL No. :	MFCD08276180
Formula :	C₈H₅ClN₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DOFQCJUTUJSCOP-UHFFFAOYSA-N
M.W :	180.59	Pubchem ID :	23160273
Synonyms :

Safety of [ 848438-50-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 848438-50-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 848438-50-6 ]
Downstream synthetic route of [ 848438-50-6 ]

[ 848438-50-6 ] Synthesis Path-Upstream 1~6

1
[ 848438-50-6 ]
[ 74-88-4 ]
[ 50424-28-7 ]

Yield	Reaction Conditions	Operation in experiment
51%	With potassium carbonate In N,N-dimethyl-formamide at 65℃; for 5.5 h; Inert atmosphere; Sealed tube	In a seal tube under argon, 16 (80.0 mg, 0.443 mmol) and K₂CO₃ (91.8 mg, 0.664 mmol) were dissolved in 2.30 mL of DMF. Iodomethane (33.1 μL, 0.532 mmol) was added and the reaction was stirred 5.5 h at 65 °C. H₂O was added and the aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄ and the solvent was removed under vacuum. The product was purified by flash column chromatography using hexane/EtOAc (60:40) to afford 17 as a white solid (43.6 mg, 51percent). Mp: 129-131 °C; IR (ATR, ZnSe): ν (cm^-1) 2919, 1561, 1494, 1397, 1218, 836, 731, 679; ¹H NMR (500 MHz, CDCl₃): δ (ppm) 8.90 (s, 1H), 7.93 (d, J = 9.2 Hz, 1H), 7.56 (dd, J = 9.2, 2.8 Hz, 1H), 7.38 (d, J = 2.8 Hz, 1H), 3.97 (s, 3H). C NMR (126 MHz, CDCl₃): δ (ppm) 160.5, 159.6, 151.7, 147.4, 130.4, 128.1, 125.2, 102.7, 56.0; HRMS-ESI calcd for C₉H₈ClN₂O [M+H]⁺ 195.0320 found 195.0313.

Reference： [1] European Journal of Medicinal Chemistry, 2018, vol. 147, p. 130 - 149

2
[ 848438-50-6 ]
[ 109-86-4 ]
[ 937263-67-7 ]

Yield	Reaction Conditions	Operation in experiment
87%	With di-isopropyl azodicarboxylate; triphenylphosphine In dichloromethane at 20℃; for 16 h;	Step F: Preparation of 4-chloro-6-(2-methoxyethoxy)quinazoline: To a solution of 4-chloroquinazolin-6-ol (1.00 g, 5.54 mmol), triphenyl phosphine (1.45 g, 5.54 mmol) and 2-methoxyethanol (0.421 g, 5.54 mmol) in dichloromethane (83 mL) was added diisopropyl azodicarboxylate (1.18 g, 5.54 mmol). After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure. The residue was chromatographed (30percent ethyl acetate in hexanes) to provide the product (1.15 g, 87percent) as white solid.

Reference： [1] Patent: EP2090575, 2009, A1, . Location in patent: Page/Page column 62

3
[ 179246-11-8 ]
[ 848438-50-6 ]

Yield	Reaction Conditions	Operation in experiment
80%	With ammonia In methanol for 1 h;	Step E: Preparation of 4-chloroauinazolin-6-ol: A mixture of 4-chloroquinazolin-6-yl acetate (10.0 g, 44.9 mmol) and ammonia (200 mL of 7N solution in methanol) were stirred together for 1 hour. The reaction mixture was concentrated to about 3 mL and triturated with diethyl ether to provide the product (6.50 g, 80percent) as tan solid.
80%	for 1 h;	4-Chloroquinazolin-6-yl acetate (7.61 g) was dissolved in 7N ammonia in methanol (100 ml) and stirred under nitrogen for LH. The solution was reduced in volume to about 2 ml and triturated with diethyl ether to give 4-chloroquinazolin-6-ol (4.20 g, 80percent) as a beige solid; NMR spectrum (DMSO-d6) 8.85 (s, 1H), 7.96 (d, 1H), 7.61 (dd, 1H), 7.40 (d, 1H).
67%	With ammonia In methanol at 20℃; for 3 h; Inert atmosphere	Under argon, 15 (960 mg, 4.33 mmol) was dissolved in a solution of NH₃ (15.5 mL, 108 mmol, 7 N in CH₃OH). The mixture was stirred 3 h at room temperature. After completion of the reaction, the solvent was removed under vacuum. The solid was triturated with diethyl ether, filtrated to afford 16 as a beige solid (519 mg, 67percent). Mp: 260 °C (dec.); IR (ATR, ZnSe): ν (cm^-1) 3128, 3044, 1557, 1490, 1359, 1244, 943, 829, 692; ¹H NMR (500 MHz, DMSO-d₆): δ (ppm) 10.88 (br s, 1H), 8.89 (s, 1H), 7.98 (d, J = 9.0 Hz, 1H), 7.65 (dd, J = 9.1, 2.7 Hz, 1H), 7.42 (d, J = 2.7 Hz); ¹³C NMR (126 MHz, DMSO-d₆): δ (ppm) 159.0, 158.1, 150.7, 145.6, 130.3, 128.0, 124.6, 105.5; HRMS-ESI calcd for C₈H₄ClN₂O [M-H]^- 179.0018 found 179.0030.

Reference： [1] Patent: EP2090575, 2009, A1, . Location in patent: Page/Page column 62
[2] Patent: WO2005/26151, 2005, A1, . Location in patent: Page/Page column 113
[3] Patent: WO2011/130459, 2011, A1, . Location in patent: Page/Page column 60
[4] European Journal of Medicinal Chemistry, 2018, vol. 147, p. 130 - 149

4
[ 179688-15-4 ]
[ 848438-50-6 ]

Reference： [1] European Journal of Medicinal Chemistry, 2018, vol. 147, p. 130 - 149

5
[ 394-31-0 ]
[ 848438-50-6 ]

Reference： [1] European Journal of Medicinal Chemistry, 2018, vol. 147, p. 130 - 149

6
[ 16064-10-1 ]
[ 848438-50-6 ]

Reference： [1] European Journal of Medicinal Chemistry, 2018, vol. 147, p. 130 - 149

[ 848438-50-6 ] Synthesis Path-Downstream 1~21

1
[ 179246-11-8 ]
[ 848438-50-6 ]

Yield	Reaction Conditions	Operation in experiment
80%	With ammonia; In methanol; for 1.0h;	Step E: Preparation of 4-chloroauinazolin-6-ol: A mixture of 4-chloroquinazolin-6-yl acetate (10.0 g, 44.9 mmol) and ammonia (200 mL of 7N solution in methanol) were stirred together for 1 hour. The reaction mixture was concentrated to about 3 mL and triturated with diethyl ether to provide the product (6.50 g, 80%) as tan solid.
80%	With methanol; ammonia; for 1.0h;	4-Chloroquinazolin-6-yl acetate (7.61 g) was dissolved in 7N ammonia in methanol (100 ml) and stirred under nitrogen for LH. The solution was reduced in volume to about 2 ml and triturated with diethyl ether to give 4-chloroquinazolin-6-ol (4.20 g, 80%) as a beige solid; NMR spectrum (DMSO-d6) 8.85 (s, 1H), 7.96 (d, 1H), 7.61 (dd, 1H), 7.40 (d, 1H).
80%	With methanol; ammonia;	Intermediate 1[00166] Bioorganic & Medicinal Chemistry Letters, 14(1): 11 1-1 14 (2004). B.[00167] To a stirred solution of Part A compound (172 mg, 0.77 mmol) in methanol (3 mL) was added ammonia in methanol (7N, 6 mL, 42 mmol). After 1 h, the reaction was concentrated and water (20 mL) was added. The resulting mixture was filtered to collect Intermediate 1 (110 mg, 80%) as a white solid.

67%

With ammonia; In methanol; at 20.0℃; for 3.0h;Inert atmosphere;

Under argon, 15 (960?mg, 4.33?mmol) was dissolved in a solution of NH3 (15.5?mL, 108?mmol, 7?N in CH3OH). The mixture was stirred 3?h?at room temperature. After completion of the reaction, the solvent was removed under vacuum. The solid was triturated with diethyl ether, filtrated to afford 16 as a beige solid (519?mg, 67%). Mp: 260?C (dec.); IR (ATR, ZnSe): nu (cm-1) 3128, 3044, 1557, 1490, 1359, 1244, 943, 829, 692; 1H NMR (500?MHz, DMSO-d6): delta (ppm) 10.88 (br s, 1H), 8.89 (s, 1H), 7.98 (d, J?=?9.0?Hz, 1H), 7.65 (dd, J?=?9.1, 2.7?Hz, 1H), 7.42 (d, J = 2.7?Hz); 13C NMR (126?MHz, DMSO-d6): delta (ppm) 159.0, 158.1, 150.7, 145.6, 130.3, 128.0, 124.6, 105.5; HRMS-ESI calcd for C8H4ClN2O [M-H]- 179.0018 found 179.0030.

Reference： [1]Patent: EP2090575,2009,A1 .Location in patent: Page/Page column 62
[2]Patent: WO2005/26151,2005,A1 .Location in patent: Page/Page column 113
[3]Patent: WO2011/130459,2011,A1 .Location in patent: Page/Page column 60
[4]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149

2
[ 848438-50-6 ]
[ 109384-19-2 ]
[ 848438-51-7 ]

Yield	Reaction Conditions	Operation in experiment
96%	With di-isopropyl azodicarboxylate; triphenylphosphine; In dichloromethane; for 20.0h;	4-Chloroquinazolin-6-ol (250 mg) in DCM (10 ml) was treated with triphenylphosphine (540 mg), 1-TERT-BUTOXYCARBONYL-4-HYDROXYPIPERIDINE (414 mg) and DIAD (420 mg) and stirred under nitrogen for 20 hours. The solution was purified by chromatography using ethyl acetate-isohexane as eluant to give tert-butyl 4- [ (4- chloroquinazolin-6-yl) oxy] PIPERIDINE-1-CARBOXYLATE (96%) as a white solid; Mass spectrum MH+ 364.

Reference： [1]Patent: WO2005/26151,2005,A1 .Location in patent: Page/Page column 113-114

3
[ 848438-50-6 ]
[ 129999-45-7 ]
[ 848438-59-5 ]

Yield	Reaction Conditions	Operation in experiment
78%	With di-tert-butyl-diazodicarboxylate; triphenylphosphine; for 20.0h;	4-Chloroquinazolin-6-ol (900 mg, 4.8 mmol) in dichloromethane (40 ML) was treated with triphenylphosphine (1.6 g, 6 mmol), 1-DIMETHYLAMINOACETYL-4-HYDROXYPIPERIDINE (900 mg, 4.8 mmol) and DI-TERT-BUTYLAZADICARBOXYLATE (1.4 g, 6 mmol) and stirred under nitrogen for 20 hours. The solution was purified by chromatography using 0 to 2% methanolic ammonia in dichloromethane as eluant to give 4-CHLORO-6- (F 1- [ (DIMETHYLAMINO) acetyl] piperidin-4-yl} oxy) quinazoline (1.09 g, 78%) as a white solid; Mass spectrum MH+ 349.

Reference： [1]Patent: WO2005/26151,2005,A1 .Location in patent: Page/Page column 121

4
[ 848438-50-6 ]
[ 19444-84-9 ]
[ 1213827-20-3 ]

Yield	Reaction Conditions	Operation in experiment
	With triphenylphosphine; diethylazodicarboxylate; In tetrahydrofuran; at 20.0℃; for 10.0h;	4-Chloro-6-hydroxy-quinazoline (77 mg; 0.43 mmol), 131 mg (1.28 mmol) of 2-hydroxy-butyrolactone and 336 mg (1.28 mmol) of triphenyl phosphine were dissolved in 7 ml of THF and 558 mg (1.28 mmol) of diethyl azodicarboxylate was added thereto at room temperature. The reaction solution was further stirred at room temperature for 10 hours, water was added thereto and the mixture was extracted with chloroform. The organic layer was dried and concentrated and the resulting residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 1:1) to give 4-chloro-6-(butyrolactone-2-yloxy)-quinazoline. The resulting chloro compound was heated to stirr at 140C for 30 minutes with 60 mg (0.147 mmol) of 1-methyl-1H-pyrazole-3-amine in 0.2 ml of phenol. Chloroform was added to the reaction solution and the mixture was washed with a saturated aqueous solution of sodium hydrogen carbonate. The organic layer was dried and concentrated and the resulting residue was purified by a reversed phase preparative HPLC (0.1% TFA-containing water : acetonitrile = 90:10 ? 10:90) to give 1 mg (yield: 1%) of the title compound as a yellow solid. 1 HNMR (CDCl3) delta: 2.39-2.44 (1H, m), 2.95-2.96 (1H, m), 3.89 (3H, s), 4.39-4.46 (1H, m), 4.51-4.53 (1H, m), 5.35-5.38 (1H, m), 6.73-6.75 (1H, m), 7.32-7.33 (1H, m), 7.52-7.53 (1H, m), 7.85 (1H, d, J=8.6Hz), 8.17 (1H, s), 8.51 (1H, s) ESI-MS(m/e):326[M+H]+

Reference： [1]Patent: EP1734040,2006,A1 .Location in patent: Page/Page column 62-63

5
[ 848438-50-6 ]
[ 453-13-4 ]
[ 865663-85-0 ]

Yield	Reaction Conditions	Operation in experiment
80%	With triphenylphosphine; diethylazodicarboxylate; In tetrahydrofuran; at 20.0℃; for 2.0h;	Example 1 A.[00187] To a stirred solution of Intermediate 1 (70 mg, 0.39 mmol), 1,3-difluoro 2- propanol (112 mg, 1.16 mmol) and triphenyl phosphine (304 mg, 1.16 mmol) in THF (3 mL) was added DEAD (202 mg, 1.16 mmol) dropwise. The reaction was kept at RT for 2 h and was concentrated. The residue was diluted with CH2CI2 and washed with sat aHC03 solution. The organic phase was washed with brine (10 mL), dried (MgS04), and concentrated in vacuo. The resulting mixture was purified by silica gel column (10-100% EtOAc in hexanes) to give the Part A compound (80 mg, 80% yield) as a white solid.
74%	With triphenylphosphine; In tetrahydrofuran; at 20.0℃; for 3.0h;	4-Chloro-6-hydroxy-quinazoline (500 mg; 2.78 mmol), 800 mg (8.33 mmol) of 1,3-difluoro-2-propanol and 2.18 g (8.33 mmol) of triphenyl phosphine were dissolved in 30 ml of THF and 3.62 g (8.33 mmol) was added thereto at room temperature. The reaction solution was stirred at room temperature for 3 hours more, a saturated aqueous solution of sodium hydrogen carbonate was added and the mixture was extracted with chloroform. The organic layer was dried and concentrated and the resulting residue was purified by a silica gel column chromatography (hexane : ethyl acetate = 1:2) to give 530 mg (yield: 74%) of 4-chloro-6-(2-fluoro-1-fluoromethyl-ethoxy)-quinazoline as a yellow solid. The resulting chloro compound (38 mg; 0.147 mmol) and 22 mg (0.147 mmolo) of thiazolo[5,4-b]pyridin-2-yl-amine were heated at 140C for 2 hours with stirring in 0.2 ml of phenol. Chloroform was added to the reaction solution and the mixture was washed with 1N aqueous solution of sodium hydroxide. The organic layer was dried and concentrated and the resulting residue was purified by a thin layer silica gel chromatography (chlloroform : methanol = 10:1) to give 15 mg (yield: 27%) of the title compound as a yellow solid. 1 HNMR (CDCl3) delta: 4.70-4.73 (2H, m), 4.84-4.86 (2H, m), 4.90-5.02 (2H, m), 7.36 (1H, dd, J = 8.0, 4.4Hz), 7.49 (1H, dd, J = 8.8, 2.8Hz), 7.74 (1H, d, J = 8.8Hz), 7.98 (1H, dd, J = 8.0, 1.6Hz), 8.04 (1H, d, J = 2.8Hz), 8.22 (1H, s), 8.45 (1H, dd, J = 4.4, 1.2Hz) ESI-MS(m/e):374[M+H]+

Reference： [1]Patent: WO2011/130459,2011,A1 .Location in patent: Page/Page column 68; 69
[2]Patent: EP1734040,2006,A1 .Location in patent: Page/Page column 33

6
[ 848438-50-6 ]
[ 109-86-4 ]
[ 937263-67-7 ]

Yield	Reaction Conditions	Operation in experiment
87%	With di-isopropyl azodicarboxylate; triphenylphosphine; In dichloromethane; at 20.0℃; for 16.0h;	Step F: Preparation of 4-chloro-6-(2-methoxyethoxy)quinazoline: To a solution of <strong>[848438-50-6]4-chloroquinazolin-6-ol</strong> (1.00 g, 5.54 mmol), triphenyl phosphine (1.45 g, 5.54 mmol) and 2-methoxyethanol (0.421 g, 5.54 mmol) in dichloromethane (83 mL) was added diisopropyl azodicarboxylate (1.18 g, 5.54 mmol). After stirring at room temperature for 16 hours, the mixture was concentrated under reduced pressure. The residue was chromatographed (30% ethyl acetate in hexanes) to provide the product (1.15 g, 87%) as white solid.

Reference： [1]Patent: EP2090575,2009,A1 .Location in patent: Page/Page column 62

7
[ 848438-50-6 ]
[ 1341125-20-9 ]

Reference： [1]Patent: WO2011/130459,2011,A1

8
[ 848438-50-6 ]
[ 590-17-0 ]
[(4-chloroquinazolin-6-yl)oxy]acetonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate; In N,N-dimethyl-formamide; at 20.0℃; for 3.0h;Inert atmosphere;	Bromoacetonitrile (0.075 ml, 1.107 mmol) was added to a solution of <strong>[848438-50-6]4-chloroquinazolin-6-ol</strong> (0.1 g, 0.554 mmol) and cesium carbonate (0.361 g, 1.107 mmol) in DMF (2.77 mL), all under an atmosphere of argon. The reaction was stirred for 3 h at rt. The reaction was diluted with water and extracted with EtOAc (3x), the combined organic layers were then washed with water and brine, dried over anhydrous sodium sulfate, filtered and the material was used without further purification. MS: 220 (M+l).

Reference： [1]Patent: WO2016/53772,2016,A1 .Location in patent: Page/Page column 34

9
[ 848438-50-6 ]
N-(2-(1-(6-methoxyquinazolin-4-yl)piperidin-4-yl)ethyl)sulfamide [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149

10
[ 848438-50-6 ]
[ 74-88-4 ]
[ 50424-28-7 ]

Yield	Reaction Conditions	Operation in experiment
51%	With potassium carbonate; In N,N-dimethyl-formamide; at 65.0℃; for 5.5h;Inert atmosphere; Sealed tube;	In a seal tube under argon, 16 (80.0?mg, 0.443?mmol) and K2CO3 (91.8?mg, 0.664?mmol) were dissolved in 2.30?mL of DMF. Iodomethane (33.1?muL, 0.532?mmol) was added and the reaction was stirred 5.5?h?at 65?C. H2O was added and the aqueous layer was extracted with CH2Cl2. The organic layer was dried over MgSO4 and the solvent was removed under vacuum. The product was purified by flash column chromatography using hexane/EtOAc (60:40) to afford 17 as a white solid (43.6?mg, 51%). Mp: 129-131?C; IR (ATR, ZnSe): nu (cm-1) 2919, 1561, 1494, 1397, 1218, 836, 731, 679; 1H NMR (500?MHz, CDCl3): delta (ppm) 8.90 (s, 1H), 7.93 (d, J?=?9.2?Hz, 1H), 7.56 (dd, J?=?9.2, 2.8?Hz, 1H), 7.38 (d, J?=?2.8?Hz, 1H), 3.97 (s, 3H). C NMR (126?MHz, CDCl3): delta (ppm) 160.5, 159.6, 151.7, 147.4, 130.4, 128.1, 125.2, 102.7, 56.0; HRMS-ESI calcd for C9H8ClN2O [M+H]+ 195.0320 found 195.0313.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149

11
[ 179688-15-4 ]
[ 848438-50-6 ]

Yield	Reaction Conditions	Operation in experiment
68%	With thionyl chloride; In N,N-dimethyl-formamide;Reflux;	[0204] To a solution of 4-oxo-3,4-dihydroquinazolin-6-yl acetate (5.0 g, 24.4 mmol) in SOC12 (50 mL) was added DMF (1 mL). The reaction mixture was stirred at reflux overnight. The resulting mixture was evaporated and to the residue was added toluene (30 mL) and stirred at room temperature for 20 minutes. The solid was filtered and dried in vacuo to afford 4-chloroquinazolin-6-ol (3.0 g, 68% yield) as a tan solid.

Reference： [1]Patent: WO2019/60611,2019,A1 .Location in patent: Paragraph 0204
[2]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149

12
[ 394-31-0 ]
[ 848438-50-6 ]

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149

13
[ 16064-10-1 ]
[ 848438-50-6 ]

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 147,p. 130 - 149
[2]Patent: WO2019/60611,2019,A1

14
[ 848438-50-6 ]
2,3,4,5-tetrahydro-[1,3]diazepino[1,2-c]quinazolin-11-ol [ No CAS ]

Reference： [1]Patent: WO2019/60611,2019,A1

15
[ 848438-50-6 ]
2-fluoro-6-((2,3,4,5-tetrahydro-[1,3]diazepino[1,2-c]quinazolin-11-yl)oxy)benzonitrile [ No CAS ]

Reference： [1]Patent: WO2019/60611,2019,A1

16
[ 848438-50-6 ]
N-(2-cyano-3-((2,3,4,5-tetrahydro-[1,3]diazepino[1,2-c]quinazolin-11-yl)oxy)phenyl)propane-1-sulfonamide [ No CAS ]

Reference： [1]Patent: WO2019/60611,2019,A1

17
[ 848438-50-6 ]
[ 13325-10-5 ]
4-((4-hydroxybutyl)amino)quinazolin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
62%	With triethylamine; In isopropyl alcohol; for 1.0h;Cooling with ice; Reflux;	[0205] To a solution of <strong>[848438-50-6]4-chloroquinazolin-6-ol</strong> (1.0 g, 5.56 mmol) and 4-aminobutan-1- ol (1.0 g, 11.1 mmol) in isopropanol (20 mL) was added Et3N (1.7 g, 16.8 mmol) at ice- water. The reaction mixture was stirred at reflux for 1 hour. The resulting mixture was evaporated and the residue was purified by column chromatography on silica gel (DCM/MeOH from 100:1 to 20:1, v/v) to afford 4-((4-hydroxybutyl)amino)quinazolin-6-ol (0.8 g, 62% yield) as a white solid.

Reference： [1]Patent: WO2019/60611,2019,A1 .Location in patent: Paragraph 0205

18
[ 848438-50-6 ]
[ 6373-46-2 ]
[ 179246-81-2 ]

Yield	Reaction Conditions	Operation in experiment
68%	With N-ethyl-N,N-diisopropylamine; In ethanol; for 18.0h;Reflux;	General procedure: 4-chloroquin(az)olinederivative (1.0 eq.), aniline derivative (1.1 eq.), and iPr2NEt (2.5 eq.) were suspended inethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatographyusing EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solventremoval under reduced pressure, the product was obtained as a free following solid orrecrystallized from ethanol/water. 4-[4-(benzyloxy)phenyl]amino}quinazolin-6-ol(1) as a yellow solid (68 %, 220 mg, 0.640 mmol) MP 231-233 C; 1H NMR (400 MHz,DMSO-d6) delta 11.21 (s, 1H), 10.91 (s, 1H), 8.75 (s, 1H), 8.04 (d, J = 2.5 Hz, 1H), 7.88 (d, J= 9.0 Hz, 1H), 7.70 (dd, J = 9.1, 2.5 Hz, 1H), 7.62 - 7.57 (m, 2H), 7.52 - 7.44 (m, 2H),7.44 - 7.37 (m, 2H), 7.37 - 7.30 (m, 1H), 7.14 - 7.09 (m, 2H), 5.16 (s, 2H). 13C NMR (101MHz, DMSO-d6) delta 158.8, 157.8, 156.7, 148.1, 136.9, 131.6, 129.7, 128.5 (2C, s), 127.9,127.7 (2C, s), 126.5, 126.2 (2C, s), 121.2, 114.92, 114.85 (2C, s), 107.1, 69.4. HRMS m/z[M+H]+ calcd for C21H18N3O2: 344.1399 found = 344.1386; LC tR = 4.24 min,>98 %Purity.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 2695 - 2699

19
[ 848438-50-6 ]
[ 53234-85-8 ]
4-({4-[(4-fluorophenyl)methoxy]phenyl}amino)quinazolin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
76%	With N-ethyl-N,N-diisopropylamine; In ethanol; for 18.0h;Reflux;	General procedure: 4-chloroquin(az)olinederivative (1.0 eq.), aniline derivative (1.1 eq.), and iPr2NEt (2.5 eq.) were suspended inethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatographyusing EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solventremoval under reduced pressure, the product was obtained as a free following solid orrecrystallized from ethanol/water.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 2695 - 2699

20
[ 848438-50-6 ]
[ 202197-25-9 ]
4-({4-[(3-fluorophenyl)methoxy]phenyl}amino)quinazolin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
58%	With N-ethyl-N,N-diisopropylamine; In ethanol; for 18.0h;Reflux;	General procedure: 4-chloroquin(az)olinederivative (1.0 eq.), aniline derivative (1.1 eq.), and iPr2NEt (2.5 eq.) were suspended inethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatographyusing EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solventremoval under reduced pressure, the product was obtained as a free following solid orrecrystallized from ethanol/water.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 2695 - 2699

21
[ 848438-50-6 ]
[ 57181-83-6 ]
4-({4-[(2-fluorophenyl)methoxy]phenyl}amino)quinazolin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
69%	With N-ethyl-N,N-diisopropylamine; In ethanol; for 18.0h;Reflux;	General procedure: 4-chloroquin(az)olinederivative (1.0 eq.), aniline derivative (1.1 eq.), and iPr2NEt (2.5 eq.) were suspended inethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatographyusing EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solventremoval under reduced pressure, the product was obtained as a free following solid orrecrystallized from ethanol/water.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 2695 - 2699

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

• Acid-Catalyzed α -Halogenation of Ketones • Acidity of Phenols • Add Hydrogen Cyanide to Aldehydes and Ketones to Produce Alcohols • Addition of a Hydrogen Halide to an Internal Alkyne • Alcohol Syntheses from Aldehydes, Ketones and Organometallics • Alcohols are Weakly Basic • Alcohols as Acids • Alcohols Convert Acyl Chlorides into Esters • Alcohols from Haloalkanes by Acetate Substitution-Hydrolysis • Alcohols React with PX3 • Alcoholysis of Anhydrides • Aldehydes and Ketones Form Hemiacetals Reversibly • Aldol Addition • Alkene Hydration • Alkene Hydration • Alkyl Halide Occurrence • Alkylation of an Alkynyl Anion • An Alkane are Prepared from an Haloalkane • Appel Reaction • Base-Catalyzed Hydration of α,β -Unsaturated Aldehydes and Ketones • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Carboxylic Acids React with Alcohols to Form Esters • Chan-Lam Coupling Reaction • Chloroalkane Synthesis with SOCI2 • Chromium Reagents for Alcohol Oxidation • Chugaev Reaction • Claisen Condensations Produce β-Dicarbonyl Compounds • Claisen Condensations Produce β-Dicarbonyl Compounds • Conjugate Additions of p-Benzoquinones • Convert Esters into Aldehydes Using a Milder Reducing Agent • Convert Haloalkanes into Alcohols by SN2 • Corey-Kim Oxidation • Decarboxylation of 3-Ketoacids Yields Ketones • Decomposition of Arenediazonium Salts to Give Phenols • Decomposition of Lithium Aluminum Hydride by Protic Solvents • Dess-Martin Oxidation • Diazo Coupling • Electrophilic Substitution of the Phenol Aromatic Ring • Esters Are Reduced by LiAlH4 to Give Alcohols • Esters Hydrolyze to Carboxylic Acids and Alcohols • Ether Synthesis by Oxymercuration-Demercuration • Etherification Reaction of Phenolic Hydroxyl Group • Ethers Synthesis from Alcohols with Strong Acids • Friedel-Crafts Alkylation of Benzene with Haloalkanes • Friedel-Crafts Alkylations Using Alcohols • Geminal Diols and Acetals Can Be Hydrolyzed to Carbonyl Compounds • General Reactivity • Grignard Reaction • Grignard Reagents Transform Esters into Alcohols • Grignard Reagents Transform Esters into Alcohols • Haloalcohol Formation from an Alkene Through Electrophilic Addition • Halogen and Alcohols Add to Alkenes by Electrophilic Attack • Halogen and Alcohols Add to Alkenes by Electrophilic Attack • Halogenation of Alkenes • Halogenation of Phenols • Hemiaminal Formation from Amines and Aldehydes or Ketones • Hemiaminal Formation from Amines and Aldehydes or Ketones • HIO4 Oxidatively Degrades Vicinal Diols to Give Carbonyl Derivatives • Hiyama Cross-Coupling Reaction • Hydration of the Carbonyl Group • Hydride Reductions • Hydride Reductions of Aldehydes and Ketones to Alcohols • Hydride Reductions of Aldehydes and Ketones to Alcohols • Hydroboration-Oxidation • Hydroboration-Oxidation • Hydrolysis of Haloalkanes • Jones Oxidation • Ketones Undergo Mixed Claisen Reactions to Form β-Dicarbonyl Compounds • Kinetics of Alkyl Halides • Kolbe-Schmitt Reaction • Kumada Cross-Coupling Reaction • Martin's Sulfurane Dehydrating Reagent • Methylation of Ammonia • Mitsunobu Reaction • Moffatt Oxidation • Osmium Tetroxide Reacts with Alkenes to Give Vicinal Diols • Osmium TetroxideReacts with Alkenes to Give Vicinal Diols • Oxidation of Alcohols by DMSO • Oxidation of Phenols • Oxymercuration-Demercuration • Pechmann Coumarin Synthesis • Preparation of Alcohols • Preparation of Aldehydes and Ketones • Preparation of Alkenes by Dehydration of Alcohols • Preparation of Alkenes by Dehydration of Alcohols • Preparation of Alkoxides with Alkyllithium • Preparation of Amines • Primary Ether Cleavage with Strong Nucleophilic Acids • Reactions of Alcohols • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions with Organometallic Reagents • Reduction of an Ester to an Alcohol • Reduction of Carboxylic Acids by LiAlH4 • Reduction of Carboxylic Acids by Lithium Aluminum Hydride • Reduction of Carboxylic Acids by Lithium Aluminum Hydride • Reimer-Tiemann Reaction • Ring Opening of an Oxacyclopropane by Lithium Aluminum Hydride • Ritter Reaction • Sharpless Olefin Synthesis • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling • Swern Oxidation • Synthesis of Alcohols from Tertiary Ethers • Synthesis of an Alkyl Sulfonate • The Claisen Rearrangement • The Nucleophilic Opening of Oxacyclopropanes • Thiazolium Salt Catalysis in Aldehyde Coupling • Thiazolium Salts Catalyze Aldehyde Coupling • Thiazolium Salts Catalyze Aldehyde Coupling • Transesterification • Use 1,3-dithiane to Prepare of α-Hydroxyketones • Vicinal Anti Dihydroxylation of Alkenes • Williamson Ether Syntheses

Historical Records

Related Functional Groups of
[ 848438-50-6 ]

Chlorides

[ 155960-92-2 ]

4-Chloro-6-ethoxyquinazoline

Similarity: 0.95

[ 55496-52-1 ]

4-Chloro-7-methoxyquinazoline

Similarity: 0.93

[ 105763-77-7 ]

2,4-Dichloro-6-methoxyquinazoline

Similarity: 0.87

[ 60395-90-6 ]

4-Chloro-6-methoxy-2-methylquinazoline

Similarity: 0.86

[ 884340-91-4 ]

4-Chloro-5,7-dimethoxyquinazoline

Similarity: 0.86

Alcohols

[ 19181-64-7 ]

6-Methoxyquinazolin-4-ol

Similarity: 0.74

[ 179688-01-8 ]

7-(Benzyloxy)-6-methoxyquinazolin-4(3H)-one

Similarity: 0.73

[ 16064-14-5 ]

6-Chloroquinazolin-4-ol

Similarity: 0.71

[ 674810-96-9 ]

4-(4-Methoxyphenyl)pyrimidin-2-ol

Similarity: 0.71

[ 62484-12-2 ]

7-Methoxyquinazoline-2,4-diol

Similarity: 0.69

Related Parent Nucleus of
[ 848438-50-6 ]

Quinazolines

[ 155960-92-2 ]

4-Chloro-6-ethoxyquinazoline

Similarity: 0.95

[ 55496-52-1 ]

4-Chloro-7-methoxyquinazoline

Similarity: 0.93

[ 105763-77-7 ]

2,4-Dichloro-6-methoxyquinazoline

Similarity: 0.87

[ 60395-90-6 ]

4-Chloro-6-methoxy-2-methylquinazoline

Similarity: 0.86

[ 884340-91-4 ]

4-Chloro-5,7-dimethoxyquinazoline

Similarity: 0.86

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 848438-50-6 ] {[proInfo.proName]}

Quality Control of [ 848438-50-6 ]

Related Doc. of [ 848438-50-6 ]

Product Details of [ 848438-50-6 ]

Safety of [ 848438-50-6 ]

Application In Synthesis of [ 848438-50-6 ]

[ 848438-50-6 ] Synthesis Path-Upstream 1~6

[ 848438-50-6 ] Synthesis Path-Downstream 1~21

Technical Information

Related Functional Groups of [ 848438-50-6 ]

Chlorides

Alcohols

Related Parent Nucleus of [ 848438-50-6 ]

Quinazolines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 848438-50-6 ]

Related Parent Nucleus of
[ 848438-50-6 ]